NCI-H358 Transfection Reagent (Bronchioalveolar Cells)

Altogen Biosystems is a global producer and custom research organization for the pharmaceutical industry. Biological products and other goods include ELISA testing, optimization of preclinical research, stable transfection of cells, IND applications and more. Dedicated to helping researchers with state-of-the-art and efficient services, Altogen Biosystems strives to further modern clinical techniques. Visit the Altogen Biosystems website for lung xenograft models and related tools for preclinical drug testing.

Derived from the bronchioalveolar cancer of a human patient by A.F. Gazdar in 1981, the NCI-H358 cell line has served as a stable testing environment for lung cancer drug evaluations during preclinical trials. As an in vitro model for the testing of drugs, the NCI-H358 cell line can be transfected with optimal reagents to ensure the realistic nature of results pertaining to genetic mutations and resulting effects on cell proliferation. With a population doubling time of roughly 38 hours, the cell line is well-suited for preclinical research and drug testing that may lead to clinical trials.

The NCI-H358 cell line was first established in 1981 from removed bronchiole tissue of a patient suffering from  bronchioalveolar carcinoma (lung cancer). The tissue was removed from the patient prior to any administered chemotherapy treatments.  The NCI-H358 cell line has a doubling time of about 38 hours, it has detectable Clara cells and is an exceptional transfection host. This cell line is also a  great candidate for  in vitro research  studies, such as those at Altogen Biosystems . T he   in vitro research models are helpful to solving lung cancer and useful as transfection hosts.  Transfection Reagent for NCI-H358 Cells (Bronchioalveolar Cells, CRL-5807)